ABSI Earnings

ABSI reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 378.00K against an estimate of 2.00M, resulting in a -76.07% surprise. The EPS was -0.2, surpassing the expected -0.19 by -5.26% . The stock experienced a -22.35% price change on the earnings day and a -16.47% change over the next five days, reflecting market reactions to the results.

Following ABSI's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -22.35% on the day of the release. Over the subsequent five days, it saw a -16.47% change. Historically, ABSI's stock price tends to shift by an average of +6.45% in the 10 days leading up to earnings and +1.95% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ABSI’s annual revenue to reach 1.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -24% and EPS estimates Revise Upward by 0.87% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ABSI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -24%, while EPS estimates moved Revise Upward by 0.87% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ABSI's stock price typically moves by +6.45% in the 10 days before its earnings and +1.95% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 1.00M.

The company's earnings call reflects positive financial performance, with increased cash reserves and reduced expenses. The strategic focus on advancing clinical trials and potential new partnerships, especially with large pharma, is promising. Despite some management vagueness, the Q&A session highlights optimism in drug development and partnerships, particularly for ABS-101 and ABS-201. The financial health and strategic partnerships suggest a positive stock price movement, although the lack of specific market cap data tempers expectations from a strong positive rating.